Bio-Outsourcing

Bioluminescence Ventures to invest $477 million in biotech startups

02-Nov-2023 By Jonathan Smith

The US investment firm Bioluminescence Ventures (BLV) has emerged from stealth with $477 million to finance biotech companies developing first-in-class or best-in-class disease treatments.

Aragen launches $30 million biologics manufacturing facility

02-Nov-2023 By Jonathan Smith

The Indian contract research development and manufacturing organization (CRDMO) Aragen Life Sciences will invest $30 million in building a 160,000 square-meter biologics manufacturing facility in Bangalore.

Novartis cites strong sales growth for $15B Sandoz spin-off as board vote unanimously for separation

21-Aug-2023 By Liza Laws

Novartis’ board of directors has unanimously agreed to separate Sandoz as a 100 per cent spin-off with a $15 billion share buyback.

Cytiva and Pall Life Sciences complete integration: ‘Uniting gives us the focus, expertise and talent to help our customers discover, develop and deliver the next generations of novel therapeutics’

02-May-2023 By Rachel Arthur

Cytiva and the life sciences business of Pall Corporation are now united as one business under the Cytiva brand, with the completion of the integration announced this morning. Emmanuel Ligner, Danaher Group Executive, President and CEO of Cytiva, tells...

Sterling Pharma Solutions granted MIA license for cGMP antibody-drug conjugate manufacturing at UK facility

20-Apr-2023 By Rachel Arthur

CDMO Sterling Pharma Solutions has been granted a Manufacturer’s Authorisation for Investigational Medicinal Products from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

Ginkgo touts gene therapy one-stop shop capabilities following acquisition

11-Apr-2023 By Ben Hargreaves

Ginkgo acquires StrideBio's adeno-associated virus (AAV) capsid discovery and engineering platform assets and as well as gaining ownership of a preclinical asset.

New Lonza facility set to support US biotechs in managing the path to commercialization of novel therapies

14-Feb-2023 By Jane Byrne

Switzerland headquartered Lonza said it is expanding its early development services (EDS) to North America, opening a new laboratory in Cambridge, Massachusetts (US).

AGC Biologics supports commercial production of Provention Bio’s new Type 1 diabetes therapy

24-Jan-2023 By Rachel Arthur

CDMO AGC Biologics will produce Tzield (teplizumab-mzwv), a recently-approved T1D treatment from Provention Bio, at its Seattle protein biologics manufacturing site.

CBM looks to boost viral vector manufacturing capabilities in cell line deal

19-Jan-2023 By Jane Byrne

The unprecedented rise in approvals for new cell and gene therapies, and the increasing industry need for cell lines to support the production of therapeutics, has spurred US CDMO, the Center for Breakthrough Medicines (CBM), to act

Resilience to expand global footprint, collaborating on first GMP biopharma facility in UAE

17-Jan-2023 By Jane Byrne

National Resilience has secured an equity investment from Mubadala, an Abu Dhabi sovereign investor. The amount was not disclosed.

Catalent made primary commercial manufacturing partner for Sarepta’s DMD gene therapy candidate

10-Jan-2023 By Jane Byrne

Catalent is to support the manufacture of Sarepta Therapeutics' gene therapy candidate for the treatment of Duchenne muscular dystrophy (DMD).

Lonza to support manufacturing of bispecific antibody drug candidate

09-Jan-2023 By Jane Byrne

Lonza and Context Therapeutics are collaborating on the manufacture of a bispecific antibody-based therapy.

Charles River wins gene therapy manufacturing contract from Nanoscope

07-Nov-2022 By Nick Taylor

Charles River Laboratories’ growing gene therapy manufacturing capabilities have landed it a deal with the eye disease biotech Nanoscope Therapeutics.

ReiThera opens new viral vector production manufacturing facility

03-Nov-2022 By Rachel Arthur

ReiThera has received operational authorization from the Italian Medicines Agency (AIFA) to open a new production area at its facility near Rome for the large-scale production of viral vectors for vaccines and gene therapy.

‘Innovators need to meet contract services partners sooner, plan much earlier and far further into development’

26-Oct-2022 By Rachel Arthur

A ‘significant shift’ is under way in global outsourcing strategies: with the sector moving away from phase-appropriate development in favor of a more forward-looking model – with experts advising starting the search for an outsourcing partner as early...

Increased demand for aseptic filling sees Cytiva boost manufacturing capacity in Vancouver

28-Jul-2022 By Jane Byrne

This week saw Cytiva open a new 126 200 ft2 (11,724 m2) site in the greater Vancouver area, Canada.

Samsung Biologics on track to open ‘super plant’ in October

28-Jul-2022 By Rachel Arthur

Construction of Samsung Biologics’ Plant 4 is on schedule with operations set to start in October, the company confirmed in its Q2 results this morning.

WuXi Biologics to build CRDMO center in Singapore

21-Jul-2022 By Rachel Arthur

CDMO WuXi Biologics will invest $1.4bn in a 10 year investment plan to expand its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.

Exothera to support process development of Turkish company’s COVID-19 vaccine

07-Jul-2022 By Jane Byrne

Turkey based Vaccizone has chosen Belgian CDMO, Exothera, to fast-track process development of its COVID-19 vaccine for European clinical trials.

Spanish CDMO adapts production capabilities, boosts workforce to meet rising viral vector demand

27-Jun-2022 By Jane Byrne

VIVEbiotech has completed the latest expansion phase of its lentiviral vector manufacturing capabilities; the development is aimed at alleviating the viral vector bottleneck for advanced therapies.

Hanmi expands offerings with ‘high-tech’ CDMO services

27-May-2022 By Ben Hargreaves

The South Korean company moves to include the raw materials behind mRNA vaccines as part of its CDMO package.

Lonza to lend manufacturing expertise and knowledge to Israeli biotechs

24-May-2022 By Jane Byrne

Lonza has entered into a two-year agreement with Israel Biotech Fund (IBF) to support its portfolio of biotech companies.

Novartis looks to work more strategically as CDMO

16-May-2022 By Jane Byrne

Novartis has recently set up a new contract development and manufacturing unit called Global Biotech Co-operations (GBTC).

ExcellGene and Cytena team up to optimize workflows for mAb and therapeutic protein manufacturing

05-May-2022 By Jane Byrne

ExcellGene SA, a Swiss biologics focused CDMO, has established a collaboration agreement with German biological cell instrument developer, Cytena.

US and South Korean microbiome CDMO partnership to build US facility

12-Apr-2022 By Jane Byrne

List Bio, together with List Labs, is set to build a new US$125m plant in Indiana, offering end-to-end manufacturing for early-stage development through to commercial production of new microbiome therapeutics.

Vetter and Rentschler progress joint CDMO collaborative work

04-Apr-2022 By Jane Byrne

Vetter and Rentschler Biopharma are looking to boost the awareness and benefits of their strategic CDMO alliance.

Abzena secures $65m to expand production capacity, mammalian biologics site set to come online

31-Mar-2022 By Jane Byrne

Abzena, a global CDMO specializing in the integrated development and manufacture of complex biologics and bioconjugates, has secured $65M in new funding.

eTheRNA Manufacturing extends CDMO activities in LNP field

29-Mar-2022 By Jane Byrne

eTheRNA Manufacturing, a specialist RNA process developer and manufacturing member of the eTheRNA group, has introduced a new lipid nanoparticle (LNP) formulation, development and production service.

From textiles to therapies: North Carolina’s journey to a booming biotech hub

29-Mar-2022 By Rachel Arthur

While skills shortages present one of the main challenges to the biopharma industry, North Carolina believes its investments in the life science ecosystem have given it a ‘multiple decade jumpstart’ in building a successful biopharma hub for both manufacturing...

Vaccine and gene therapy focused CDMO secures GMP certification for Belgian site

25-Mar-2022 By Jane Byrne

Exothera, a CDMO specializing in the industrialization of vaccine and gene therapy processes, reports that it has achieved GMP certification for its facilities in Jumet, Belgium.

Catalent completes $30m expansion to biologics network

22-Mar-2022 By Ben Hargreaves

Catalent completes expansion of its biologics manufacturing network by upgrading its Limoges, France, location with additional capacity and the ability to produce large molecules.

Charles River expanding plasmid DNA and viral vector development in Europe

07-Mar-2022 By Jane Byrne

Charles River recently announced the expansion of its plasmid DNA and viral vector development and manufacturing capabilities in Europe; it says the move is to support the growing need of customers and to safeguard future supply.

WHO establishes global biomanufacturing training hub in Korea

25-Feb-2022 By Rachel Arthur

A global biomanufacturing training hub will be established in Korea to serve low- and middle-income countries wishing to produce biologicals such as vaccines, insulin, monoclonal antibodies and cancer treatments.

Moderna to expand commercial network across six additional countries in Europe

17-Feb-2022 By Jane Byrne

The US biotech says it will establish a commercial presence in Belgium, Denmark, Norway, the Netherlands, Poland, and Sweden to support the delivery of mRNA vaccines and therapeutics locally.

Biologics CDMO market is expanding rapidly but is challenged by capacity constraints

15-Feb-2022 By Jane Byrne

The biologics CDMO market is expected to grow by US$8.65bn from 2021 to 2026, at a CAGR of 12.2% during the forecast period, according to new market data from Technavio.

Gerresheimer boosting glass vial production capacity globally

31-Jan-2022 By Jane Byrne

Gerresheimer is expanding its capacities for glass vials at the Wertheim site in southwestern Germany, and at two further sites in China and the US.

New cell therapy focused CDMO has San Diego blood bank origins

31-Jan-2022 By Jane Byrne

A new California based CDMO has been launched, one that is focused on supporting cell therapy developers.

New year, new ADC deal: Abzena teams up with BiVictriX, Iksuda taps LegoChem again, Genmab secures access to Dutch tech

20-Jan-2022 By Jane Byrne

The past few weeks have witnessed a plethora of antibody-drug conjugate (ADC) related deals.

JP Morgan Healthcare Conference 2022

Korea’s Samsung Bio reveals massive capacity boost on the cards

13-Jan-2022 By Jane Byrne

Samsung Biologics flags further facility construction plans, with biologics, cell and gene therapies and next-generation vaccines to be the focus of those new sites.

UK market developments: GHO Capital invests in RoslinCT, Symbiosis expands viral therapy capabilities

11-Jan-2022 By Jane Byrne

Healthcare investors, GHO Capital Partners LLP, have invested in Scotland based, RoslinCT, a contract development and manufacturing organization (CDMO) focused on advanced cell therapies.

Wheeler Bio looks to solve tech transfer challenges, raises $14m in seed funding

11-Jan-2022 By Jane Byrne

Wheeler Bio, a newly established company aiming accelerate the translation of therapeutic innovation into clinical impact, recently closed a US$14m seed financing round.

G42 and Mubadala to establish biopharma manufacturing campus in Abu Dhabi

03-Jan-2022 By Jane Byrne

Abu Dhabi-based entities, the sovereign wealth fund, Mubadala Investment Company, and AI and cloud computing specialist, G42, are to set up a biopharma campus there; the move is aimed at bolstering biopharma linked innovation, R&D and manufacturing...

What are the prospects for the US gene therapy industry in 2022?

22-Dec-2021 By Jane Byrne

There is a healthy appetite for continued investment in gene therapy, in new modalities and more indications, says an industry insider as he reflected on the prospects for the US gene therapy sector next year.

SGS acquires live biotherapeutics focused CDMO

14-Dec-2021 By Jane Byrne

SGS, the Swiss-based testing, inspection and certification company, has acquired Quay Pharma, a UK based pharmaceutical industry targeted contract development and manufacturing organization (CDMO).

CDMO opens microbial-based therapeutics and mRNA vaccines facility in South Australia

13-Dec-2021 By Jane Byrne

This month saw BioCina officially open its new biologics manufacturing facility in Adelaide, Australia, flagging it as the only TGA, EMA, Health Canada and US-FDA approved commercial facility of its kind in the country.

Bora Pharmaceuticals looks to enter the cell and gene therapy CDMO space

09-Dec-2021 By Jane Byrne

Taiwan based contract manufacturer, Bora Pharmaceuticals, in partnership with Taishin Healthcare Limited, is ready to spend millions to expand its footprint in the CDMO sector.

Tech transfer box ticked in Catalent and BrainStorm cell therapy alliance

09-Dec-2021 By Jane Byrne

Catalent is reporting that the technology transfer for the manufacture of BrainStorm Cell Therapeutics’ autologous cellular therapy at its facility in Houston, Texas has been finalized.

New Fujifilm site will cater to cell culture media market demands in China

07-Dec-2021 By Jane Byrne

Fujifilm Irvine Scientific, Inc, is to build a new bioprocessing center in China, with the goal of ensuring local cell culture media optimization support for vaccines, advanced therapies, and biotherapeutic drug development.

Operations begin at new Genezen lentiviral and retroviral vector lab in Indianapolis

06-Dec-2021 By Jane Byrne

Genezen, a cell and gene therapy focused CDMO, has just opened a new process development and analytical lab, a build that represents the first phase of a 75,000+ square foot cGMP-compliant lentiviral and retroviral vector production facility in Indianapolis.

CDMO deals roundup: AGC Biologics, Halix and BioConnection support monoclonal antibody, gene therapy and vaccine projects

02-Dec-2021 By Jane Byrne

Several contract development and manufacturing organization (CDMO) supported biopharma projects have been flagged in the past month. We take a closer look.